Trials / Completed
CompletedNCT06566989
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
An Open-label Phase 1 Study to Evaluate Metabolism, Excretion, and Mass Balance of [¹⁴C]MK-5684 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics (PK), metabolic profile, and safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [¹⁴C]Opevesostat | Oral solution |
| DRUG | Prednisone | Tablet |
| DRUG | Fludrocortisone | Tablet |
Timeline
- Start date
- 2024-09-19
- Primary completion
- 2024-10-17
- Completion
- 2024-10-17
- First posted
- 2024-08-22
- Last updated
- 2024-10-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06566989. Inclusion in this directory is not an endorsement.